Skip to content

Press Releases

Filter Releases
 
Press Releases
Date Title and Summary View
Nov 6, 2012
SAN DIEGO, Nov. 6, 2012 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that its wholly owned subsidiary, Arena Pharmaceuticals GmbH, has entered into a marketing and supply agreement with Ildong Pharmaceutical Co., Ltd., for BELVIQ® (lorcaserin HCl). Under the agreement, Arena granted Ildong exclusive rights to mark...
Oct 31, 2012
SAN DIEGO, Oct. 31, 2012 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that it will provide a corporate update and report third quarter 2012 financial results after the NASDAQ Global Select Market closes on Tuesday, November 6, 2012. The company will host a conference call and webcast at 5:00 p.m. Eastern Time (2:00 p.m...
Oct 12, 2012
SAN DIEGO, Oct. 12, 2012 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today the initiation of dosing in a Phase 1 multiple dose clinical trial of APD811, a novel oral drug candidate discovered by Arena that targets the prostacyclin (IP) receptor for the treatment of pulmonary arterial hypertension (PAH). This randomiz...
Sep 18, 2012
SAN DIEGO, Sept. 18, 2012 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the company is scheduled to present a corporate overview at the UBS Global Life Sciences Conference on Thursday, September 20, 2012, at 7:30 a.m. Eastern Time (4:30 a.m. Pacific Time) at the Grand Hyatt New York in New York City. A live...
Aug 30, 2012
SAN DIEGO, Aug. 30, 2012 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the company is scheduled to present corporate updates at the following three upcoming investor conferences: Stifel Nicolaus Healthcare ConferencePresentation: September 6, 2012, at 9:10 a.m. Eastern Time (6:10 a.m. Pacific Time) at th...
Aug 9, 2012
SAN DIEGO, Aug. 9, 2012 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today reported financial results for the second quarter ended June 30, 2012, and reviewed recent developments. At June 30, 2012, cash and cash equivalents totaled $143.8 million, which does not include (i) the $20.0 million milestone payment received from Eis...
Aug 2, 2012
SAN DIEGO, Aug. 2, 2012 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that it will report second quarter 2012 financial results after the NASDAQ Global Select Market closes on Thursday, August 9, 2012. The company will host a conference call and webcast at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) that day to disc...
Jul 30, 2012
WOODCLIFF LAKE, N.J., and SAN DIEGO, July 30, 2012 /PRNewswire/ -- Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that Arena has transferred the BELVIQ® (lorcaserin hydrochloride) New Drug Application (NDA) to Eisai. The transfer establishes Eisai as the marketing authorization holder responsible for regulatory activ...
Jul 11, 2012
SAN DIEGO, July 11, 2012 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today the filing with the Swiss health authority, Swissmedic, of a Marketing Authorization Application (MAA) for lorcaserin hydrochloride, an investigational drug candidate in Switzerland. The intended indication is as an adjunct to diet and exercise for w...
Jul 9, 2012
SAN DIEGO, July 9, 2012 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the company is scheduled to present at the Seventh Annual JMP Securities Healthcare Conference on Thursday, July 12, 2012, at 9 a.m. Eastern Time (6 a.m. Pacific Time) at The Peninsula New York Hotel in New York City. Craig M. Audet, Arena's Seni...
Jul 5, 2012
SAN DIEGO, July 5, 2012 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today the promotion of Craig M. Audet to the position of Senior Vice President, Operations and Head of Global Regulatory Affairs. In his new role, Audet will serve as an executive officer of the company. Audet, 48, will oversee various operations at ...
Jun 27, 2012
SAN DIEGO and WOODCLIFF LAKE, N.J., June 27, 2012 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) and Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved BELVIQ (pronounced BEL-VEEK) as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients...
May 21, 2012
SAN DIEGO, May 21, 2012 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced the completion of an underwritten public offering of 12,650,000 shares of its common stock, including 1,650,000 shares sold pursuant to the full exercise of an over-allotment option previously granted to the underwriters. All of the shares were offere...
May 16, 2012
SAN DIEGO, May 16, 2012 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced the pricing of an underwritten public offering of 11,000,000 shares of its common stock, offered at a price to the public of $5.50 per share. The gross proceeds to Arena from this offering are expected to be $60.5 million, before deducting underwritin...
May 15, 2012
SAN DIEGO, May 15, 2012 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms ...
= add release to Briefcase